Association of Red Cell Distribution Width to Albumin Ratio with Risk of All-Cause and Cause-Specific Mortality: Two Prospective Cohort Studies
Meng Hao,Shuai Jiang,Xiangnan Li,Shuming Wang,Yi Li,Jingdong Tang,Zixin Hu,Hui Zhang
DOI: https://doi.org/10.1101/2024.01.10.24301123
2024-01-01
Abstract:Background The red cell distribution width to albumin ratio (RAR) has emerged as a reliable prognostic marker for mortality in various diseases. However, whether RAR is associated with mortality remains unknown in the general population. Objective Explore whether RAR is associated with all-cause and cause-specific mortality, and to elucidate the dose-response relationship between them. Methods This study included 50622 participants aged 18+ years from US National Health and Nutrition Examination Survey (NHANES), and 418950 participants aged 37+ years from UK Biobank. The potential association between RAR and the risk of all-cause and cause-specific mortality was evaluated by Cox proportional hazard models. Restricted cubic spline regressions were applied to estimate the possible nonlinear relationships. Results NHANES documented 7590 deaths over a median follow-up of 9.4 years, and UK Biobank documented 36793 deaths over a median follow-up of 14.5 years. In multivariable analysis, elevated RAR were significantly associated with a higher risk of all-cause mortality (NHANES: hazard ratio [HR]: 1.86, 95% confidence interval [CI]: 1.81-1.93; UK Biobank: HR: 2.01, 95% CI: 1.96-2.06), as well as mortality due to malignant neoplasms, heart disease, cerebrovascular diseases, respiratory diseases, diabetes mellitus, and others in both the two cohorts (all P-value < 0.05). Conclusions Higher baseline RAR was strongly and independently associated with increased risk of all-cause and cause-specific mortality in the general population. RAR was a promising indicator that simply, reliably, and inexpensively accessible for identifying high-risk of mortality in clinical practice. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by grants from the National Natural Science Foundation of China-Youth Science Fund (82301768, 32300533, 32100510), the Shanghai Sailing Program (23YF1430500), and the Shanghai Rising-Star Program (21QB1400900). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Data from NHANES are available at [www.cdc.gov/nchs/nhis/index.htm][1], and data from UK Biobank are available on application at [www.ukbiobank.ac.uk/register-apply][2]. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data from NHANES are available at [www.cdc.gov/nchs/nhis/index.htm][1], and data from UK Biobank are available on application at [www.ukbiobank.ac.uk/register-apply][2]. [1]: http://www.cdc.gov/nchs/nhis/index.htm [2]: http://www.ukbiobank.ac.uk/register-apply